Aceso Life Science Group Limited provided group earnings guidance for the six months ended 30 September 2023. The board of directors of the Company informed the shareholders of the Company and potential investors that, based on the preliminary assessment of the Group's unaudited consolidated management accounts for the six months ended 30 September 2023 ("Reporting Period") and information currently available to the Board, the Group is expected to record a loss for the Reporting Period of approximately HKD 250 million, as compared to the loss of approximately HKD 4 million for the corresponding period in 2022.